HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $5.75 target price on the stock. HC Wainwright’s target price points to a potential upside of 126.38% from the company’s previous close.

Separately, BTIG Research began coverage on VYNE Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $8.00 price target for the company.

VYNE Therapeutics Price Performance

Shares of NASDAQ VYNE traded up $0.04 during mid-day trading on Wednesday, reaching $2.54. The company’s stock had a trading volume of 8,219 shares, compared to its average volume of 111,309. VYNE Therapeutics has a 52 week low of $1.57 and a 52 week high of $4.30. The stock has a fifty day moving average of $2.81 and a two-hundred day moving average of $2.45. The firm has a market capitalization of $37.47 million, a PE ratio of -2.95 and a beta of 1.28.

Insider Buying and Selling at VYNE Therapeutics

In other news, Director Patrick G. Lepore purchased 15,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was acquired at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the acquisition, the director now directly owns 51,472 shares of the company’s stock, valued at $150,298.24. This represents a 41.13 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.80% of the stock is currently owned by insiders.

Institutional Trading of VYNE Therapeutics

Several hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in VYNE Therapeutics in the fourth quarter worth $68,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of VYNE Therapeutics in the 4th quarter worth $823,000. Bridgeway Capital Management LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter worth about $124,000. Schonfeld Strategic Advisors LLC increased its holdings in shares of VYNE Therapeutics by 4.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock worth $592,000 after buying an additional 8,058 shares during the last quarter. Finally, Acorn Capital Advisors LLC purchased a new stake in shares of VYNE Therapeutics during the 4th quarter valued at about $1,531,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.